

NCT00565851 GOG-0213 QOL/PRO DATA ARCHIVE

April 10, 2023

Data as of: March 7, 2019

Notes

-
- 1 Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
 - 2 DOI: 10.1056/NEJMoa1902626
 - 3 PMID: 31722153
 - 4 Clinical trial information: NCT00565851.
 - 5 Dataset ID: NCT00565851-D1
 - 6 Unless otherwise specified, blank or "." values indicate missing data.
 - 7 Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).

Var 1	Type	Label
upi	Char	Universal Patient ID
Var 2	Type	Label
country	Char	country
Code	Definition	
JP	Japan	
KR	Korea	
US	US	
Var 3	Type	Label
age	Num	Age (years)
Var 4	Type	Label
nrx_s	Num	Randomized treatment
Code	Definition	
1	No Surgery	
2	Cytoreductive Surgery	
Var 5	Type	Label
str_pfi	Num	Strata: platinum-free interval
Code	Definition	
1	PFI 6-12 months	
2	PFI >12 months	
Var 6	Type	Label
toi	Num	FACT-O TOI score

Var 7	Type	Label
pf	Num	Physical functioning subscale score
Var 8	Type	Label
surgery	Num	Surgery related side effect subscale score
Var 9	Type	Label
toi_b	Num	FACT-O TOI score at baseline
Var 10	Type	Label
toi_ch	Num	Change of FACT-O TOI after surgery for those randomized to cytoreductive surgery
Var 11	Type	Label
qol_time	Num	QOL Assessment Time
Code	Definition	
0	Baseline (prior to surgery for those randomized to cytoreductive surgery and prior to cycle 1 for those randomized to no surgery)	
1	After surgery for those randomized to cytoreductive surgery	
2	6 weeks after cycle 1/prior to cycle 3 for all patients	
3	15 weeks after cycle 1/prior to cycle 6 for all patients	
4	6 months after cycle 1 for all patients	
5	12 months after cycle 1 for all patients	
Var 12	Type	Label
str_ct	Num	Strata: chemotherapy
Code	Definition	
1	Carb+Tax	
2	Carb+Tax+Bev	
3	Carb+Gem	
4	Carb+Gem+Bev	